Lantheus Holdings LNTH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Definity | $335.66M+4.8% | $330.25M+3.9% | $331.1M+8.7% | $326.28M+10.6% | $320.44M+11.5% | |
| Licenseand Royalty Revenues | $35.67M+149% | $34.04M+273% | $19.67M-14.1% | $16.48M-14.3% | $14.31M-43.9% | |
| Neuraceq | $86.89M— | $51.45M— | $20.44M— | $0— | —— | |
| PYLARIFY | $972.39M-8.0% | $989.12M-6.5% | $1.01B-0.7% | $1.03B+5.8% | $1.06B+15.5% | |
| Strategic Partnerships And Other | $64.98M+53.2% | $59.38M+55.5% | $43.74M-17.9% | $45.28M-0.1% | $42.42M-14.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Lantheus Holdings break its business down?
- Lantheus Holdings (LNTH) reports revenue by product across 9 parts — Cardiology, Definity, Licenseand Royalty Revenues, Neuraceq and Neurology. Each is extracted from the segment footnotes and tracked over time.
- Where does Lantheus Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Lantheus Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
